3/08/2006
VCs Backing Prenatal Products
Ikonisys grabs $10M in venture funding to bring its prenatal diagnostic products to market.
Medical tech company Ikonisys said Wednesday it raised $10 million in a fourth round of venture funding to push its prenatal diagnostic products through the federal approval process and to market.
The financing will be used to complete the development of a test that will allow noninvasive prenatal detection of chromosome abnormalities. “We will be able to detect fetal cells that circulate in the maternal blood during pregnancy and to do diagnosis for chromosome abnormalities on those cells,” said Ikonisys CEO Dr. Petros Tsipouras.
fastFISH™ amnio provides automated detection of the most common chromosomal aneuploidies for chromosomes 21 (Down syndrome), 18 (Edward syndrome), 13 (Patau syndrome) as well as for numerical aberrations for sex chromosomes X and Y.
fastFISH™-PGD product provides automated pre-implantation genetic diagnosis of numerical aberrations in nine different chromosomes (13, 15, 16, 17, 18, 21, 22, X, and Y) in a single blastomere obtained from the embryo following in vitro fertilization and before implantation. Recent studies have shown that selection of chromosomally normal embryos for implantation, through chromosome FISH analysis, almost doubles the term birth rate, from 10% to approximately 20%.
will offer automated quantification of the Her-2/Neu gene an established prognostic indicator in breast cancer.
Chromotest™ will offer prenatal diagnosis of major chromosomal abnormalities using fetal cells circulating in the maternal blood.
Ikonisys' solution is non-invasive, can be administered in the first trimester of pregnancy, with a turn-around time of three days.
RED HERRING | VCs Backing Prenatal Products
Medical tech company Ikonisys said Wednesday it raised $10 million in a fourth round of venture funding to push its prenatal diagnostic products through the federal approval process and to market.
The financing will be used to complete the development of a test that will allow noninvasive prenatal detection of chromosome abnormalities. “We will be able to detect fetal cells that circulate in the maternal blood during pregnancy and to do diagnosis for chromosome abnormalities on those cells,” said Ikonisys CEO Dr. Petros Tsipouras.
fastFISH™ amnio provides automated detection of the most common chromosomal aneuploidies for chromosomes 21 (Down syndrome), 18 (Edward syndrome), 13 (Patau syndrome) as well as for numerical aberrations for sex chromosomes X and Y.
fastFISH™-PGD product provides automated pre-implantation genetic diagnosis of numerical aberrations in nine different chromosomes (13, 15, 16, 17, 18, 21, 22, X, and Y) in a single blastomere obtained from the embryo following in vitro fertilization and before implantation. Recent studies have shown that selection of chromosomally normal embryos for implantation, through chromosome FISH analysis, almost doubles the term birth rate, from 10% to approximately 20%.
will offer automated quantification of the Her-2/Neu gene an established prognostic indicator in breast cancer.
Chromotest™ will offer prenatal diagnosis of major chromosomal abnormalities using fetal cells circulating in the maternal blood.
Ikonisys' solution is non-invasive, can be administered in the first trimester of pregnancy, with a turn-around time of three days.
RED HERRING | VCs Backing Prenatal Products
